DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
CAR-T therapy shows promise in Long-Term Follow-Up for blood cancers
Disease control CompletedThis study followed 16 patients with various B-cell cancers (like lymphoma and leukemia) who had already received CLBR001 CAR-T cells. The goal was to check for long-term side effects and see how well the treatment controlled the disease over time. Researchers monitored new or la…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated May 26, 2026 07:22 UTC
-
New hope for tough blood cancers: experimental drug PRT2527 tested in early trial
Disease control CompletedThis early-stage study tested a new drug called PRT2527, alone or combined with other medicines (zanubrutinib or venetoclax), in 86 people with blood cancers that returned or didn't respond to standard treatments. The main goals were to check safety, find the best dose, and see i…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
Drug access bridge: tazemetostat rollover study offers continued treatment
Disease control CompletedThis study allowed people with certain cancers who had already benefited from the drug tazemetostat in earlier studies to keep receiving it. The main goal was to track long-term safety and side effects. Participants had already shown clinical benefit and continued treatment under…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New drug shows promise for tough blood cancers in early trial
Disease control CompletedThis early-phase study tested a new drug called Purinostat Mesylate in 29 people with blood cancers like lymphoma and leukemia that had returned or stopped responding to standard treatments. The goal was to check the drug's safety, find the best dose, and see how the body process…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tested a new drug called glofitamab combined with standard chemotherapy (R-ICE) in 43 adults with diffuse large B-cell lymphoma that returned after initial treatment. Participants were eligible for a stem cell transplant or CAR-T therapy. The goal was to see if the com…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New strategy shows promise in preventing brain spread of aggressive lymphoma
Prevention CompletedThis study tested a chemotherapy drug called thiotepa, given directly into the spinal fluid, to prevent lymphoma from spreading to the brain or spinal cord. It involved 31 adults with high-risk diffuse large B-cell lymphoma. The goal was to see if this approach is safe and effect…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Prevention
Last updated May 20, 2026 11:57 UTC
-
Genetic clues could refine lymphoma treatment
Knowledge-focused CompletedThis study looked back at tissue samples from 555 people with aggressive B-cell lymphomas to find specific genetic changes. The goal was to see if these changes could help doctors better classify the disease and choose the best treatments. The research focused on understanding, n…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Andrés José Maria Ferreri • Aim: Knowledge-focused
Last updated May 26, 2026 07:32 UTC